Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Motus GI Holdings, Inc. (MOTS)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Medical - Devices
Address
1301 East Broward Boulevard 33301
Fort Lauderdale, FL, US
Fort Lauderdale, FL, US
CEO
Mark Pomeranz
Website
motusgi.com
IPO
2018-02-14
CIK 1686850 ISIN US62014P5044
Description
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.6K
Beta
3.09
Float Shares
5.77M
Free Float %
90.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -50.00% | -50.00% | +0.00% | +0.00% | -99.98% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-35.18
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-46.1% Q1'24: +14.3% (vs Q1'23)
-
EPS growth Medical - Devices: +28.5%+81.6% ★ Q1'24: +93.6% (vs Q1'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-3,981.5% Q1'24: -3,160.9% (vs Q1'23)
-
EBIT margin Medical - Devices: +6.2%-3,795.0% Q1'24: -3,176.6% (vs Q1'23)
-
ROIC Medical - Devices: +3.3%-6,145.2% Q1'24: -1,449.6% (vs Q1'23)
-
Share dilution Medical - Devices: 0.0%+275.0% Q1'24: +2,612.4% (vs Q1'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.22× Q1'24: -0.32× (vs Q1'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
36.0K
est: 15.6K (+130.8%)
|
107.0K
est: 361.4K (-70.4%)
|
98.0K
est: 126.5K (-22.5%)
|
391.0K
est: 444.2K (-12.0%)
|
592.0K
est: 944.3K (-37.3%)
|
319.0K
est: 400.0K (-20.3%)
|
2.60M
est.
|
6.45M
est.
|
11.55M
11.55M – 11.55M
+79.1% YoY
|
| EBITDA |
-18.74M
est: -15.6K (-119,996.2%)
|
-23.21M
est: -361.4K (-6,323.1%)
|
-18.16M
est: -126.5K (-14,256.5%)
|
-17.62M
est: -444.2K (-3,865.6%)
|
-16.51M
est: -944.3K (-1,648.1%)
|
-11.43M
est: -400.0K (-2,757.3%)
|
-2.60M
est.
|
-6.45M
est.
|
-11.55M
-11.55M – -11.55M
-79.1% YoY
|
| EBIT |
-18.89M
est: -15.6K (-120,970.5%)
|
-23.44M
est: -361.4K (-6,384.8%)
|
-18.79M
est: -126.5K (-14,756.1%)
|
-18.32M
est: -444.2K (-4,023.4%)
|
-17.35M
est: -944.3K (-1,736.7%)
|
-12.11M
est: -400.0K (-2,926.5%)
|
-2.60M
est.
|
-6.45M
est.
|
-11.55M
-11.55M – -11.55M
-79.1% YoY
|
| Net Income |
-22.26M
est: -329.31M (+93.2%)
|
-23.09M
est: -224.88M (+89.7%)
|
-19.26M
est: -154.21M (+87.5%)
|
-19.03M
est: -118.51M (+83.9%)
|
-18.60M
est: -57.39M (+67.6%)
|
-12.87M
est: -19.67M (+34.6%)
|
-14.21M
est.
|
-10.93M
est.
|
-6.92M
-6.92M – -6.92M
+36.7% YoY
|
| SGA |
12.86M
est: 1.08M (+1,092.1%)
|
14.39M
est: 24.99M (-42.4%)
|
13.09M
est: 8.75M (+49.7%)
|
12.35M
est: 30.71M (-59.8%)
|
12.04M
est: 65.30M (-81.6%)
|
8.19M
est: 27.66M (-70.4%)
|
179.78M
est.
|
445.99M
est.
|
798.63M
798.63M – 798.63M
+79.1% YoY
|
| EPS |
-441.11
est: -406.80 (-8.4%)
|
-269.69
est: -277.80 (+2.9%)
|
-179.86
est: -190.50 (+5.6%)
|
-161.07
est: -146.40 (-10.0%)
|
-86.15
est: -70.90 (-21.5%)
|
-15.89
est: -24.30 (+34.6%)
|
-17.56
est.
|
-13.50
est.
|
-8.55
-8.55 – -8.55
+36.7% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.76M
OE per share TTM
-13.23
Owner's Yield
-1,249,584.36%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
692.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
20
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Armistice Capital Master Fund Ltd. | 3.09M | 9.60% | — | 3.09M | — | 3.09M | CO | Delaware | 2020-09-08 | ↗ |
| 2 | 10 | 2.87M | 18.30% | — | 2.87M | — | 2.87M | CO | Delaware | 2018-02-26 | ↗ |
| 3 | Oracle Associates, LLC | 2.78M | 13.40% | — | 2.78M | — | 2.78M | OO | United States | 2018-12-26 | ↗ |
| 4 | Oracle Investment Management, Inc. | 2.78M | 13.40% | — | 2.78M | — | 2.78M | CO | United States | 2018-12-26 | ↗ |
| 5 | Oracle Partners, LP | 2.08M | 10.00% | — | 2.08M | — | 2.08M | PN | United States | 2018-12-26 | ↗ |
| 6 | Orchestra BioMed, Inc. | 2.00M | 9.30% | 2.00M | — | 2.00M | 10.00 | CO | Delaware | 2019-02-15 | ↗ |
| 7 | David P. Hochman | 1.75M | 11.20% | 170.5K | 1.58M | 170.5K | 10.00 | IN | United States | 2018-06-11 | ↗ |
| 8 | Darren R. Sherman | 1.64M | 10.40% | 59.0K | 1.58M | 59.0K | 10.00 | IN | United States | 2018-06-11 | ↗ |
| 9 | ABV, LLC | 1.61M | 7.40% | — | 1.61M | — | — | OO | Delaware | 2019-02-13 | ↗ |
| 10 | Geoffrey W. Smith | 1.61M | 7.40% | — | 1.61M | — | — | IN | United States | 2019-02-13 | ↗ |
| 11 | Steve Hochberg | 1.61M | 7.40% | — | 1.61M | — | — | IN | United States | 2019-02-13 | ↗ |
| 12 | Orchestra MOTUS Co-Investment Partners, LLC | 1.23M | 7.80% | — | 1.23M | — | 10.00 | OO | Delaware | 2018-06-11 | ↗ |
| 13 | Ascent Biomedical Ventures II, L.P. | 907.4K | 4.20% | — | 907.4K | — | — | PN | Delaware | 2019-02-13 | ↗ |
| 14 | Orchestra BioMed Holdings, Inc. | 804.1K | 10.10% | 804.1K | — | 804.1K | — | CO | Delaware | 2023-09-22 | ↗ |
| 15 | Ascent Biomedical Ventures Synecor, L.P. | 699.8K | 3.30% | — | 699.8K | — | — | PN | Delaware | 2019-02-13 | ↗ |
| 16 | Oracle Ten Fund, LP | 412.0K | 2.00% | — | 412.0K | — | 412.0K | PN | United States | 2018-12-26 | ↗ |
| 17 | Oracle Institutional Partners, LP | 286.0K | 1.40% | — | 286.0K | — | 286.0K | PN | United States | 2018-12-26 | ↗ |
| 18 | Armistice Capital, LLC | 152.5K | 9.99% | — | 152.5K | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 19 | Steven Boyd | 152.5K | 9.99% | — | 152.5K | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 20 | Larry N. Feinberg | 105.9K | 0.22% | — | 105.9K | — | 105.9K | IN | United States | 2021-12-29 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
1.0K
Cash buys
—
Cash sales
—
Net activity
-1,006
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-01 | Ram Ravit | Officer | — | D | Stock Option (right to buy) | 1,006 | 9.20 | 9.3K | 0 | — | ↗ |
| 2024-03-05 | Pruden Gary J | Director | A-Award | A | Stock Option (right to buy) | 23,205 | 0.62 | 14.4K | 23,205 | — | ↗ |
| 2024-03-05 | Nelson Sonja | Director | A-Award | A | Stock Option (right to buy) | 23,205 | 0.62 | 14.4K | 23,205 | — | ↗ |
| 2024-03-05 | Moran Timothy P. | Director | A-Award | A | Stock Option (right to buy) | 23,205 | 0.62 | 14.4K | 23,205 | — | ↗ |
| 2024-03-05 | Durbin Scott | Director | A-Award | A | Stock Option (right to buy) | 23,205 | 0.62 | 14.4K | 23,205 | — | ↗ |
| 2023-09-12 | Orchestra BioMed Holdings, Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 804,096 | — | ↗ |
| 2023-09-06 | Durbin Scott | Director | A-Award | A | Stock Option (right to buy) | 2,500 | 0.49 | 1.2K | 2,500 | — | ↗ |
| 2023-06-02 | Amor Elad | Officer | — | D | Stock Option (right to buy) | 1,700 | 35.60 | 60.5K | 0 | — | ↗ |
| 2023-02-01 | Ram Ravit | Officer | — | D | Stock Option (right to buy) | 874 | 35.60 | 31.1K | 0 | — | ↗ |
| 2023-02-01 | Amor Elad | Officer | — | D | Stock Option (right to buy) | 2,500 | 43.20 | 108.0K | 0 | — | ↗ |
| 2022-02-10 | Taylor Andrew Lawrence | Officer | A-Award | A | Common Stock, par value $0.0001 per share | 95,000 | 0.00 | — | 230,682 | — | ↗ |
| 2022-02-10 | Sherman Darren | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.46 | 23.0K | 50,000 | — | ↗ |
| 2022-02-10 | Pruden Gary J | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.46 | 23.0K | 50,000 | — | ↗ |
| 2022-02-10 | Pomeranz Mark | Director / Officer | A-Award | A | Common Stock, par value $0.0001 per share | 95,000 | 0.00 | — | 259,857 | — | ↗ |
| 2022-02-10 | Nelson Sonja | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.46 | 23.0K | 50,000 | — | ↗ |
| 2022-02-10 | Moran Timothy P. | Director / Officer | A-Award | A | Common Stock, par value $0.0001 per share | 175,000 | 0.00 | — | 657,701 | — | ↗ |
| 2022-02-10 | Korangy Shervin J | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.46 | 23.0K | 50,000 | — | ↗ |
| 2022-02-10 | Hochman David P | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.46 | 23.0K | 50,000 | — | ↗ |
| 2022-02-01 | Ram Ravit | Officer | — | D | Stock Option (right to buy) | 618 | 86.40 | 53.4K | 0 | — | ↗ |
| 2022-01-05 | Sherman Darren | Director | A-Award | A | Common Stock, par value $0.0001 per share | 90,521 | 0.00 | — | 194,602 | — | ↗ |
| 2022-01-05 | Pruden Gary J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 106,563 | 0.00 | — | 263,116 | — | ↗ |
| 2022-01-05 | Nelson Sonja | Director | A-Award | A | Common Stock, par value $0.0001 per share | 82,500 | 0.00 | — | 100,709 | — | ↗ |
| 2022-01-05 | Korangy Shervin J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 82,500 | 0.00 | — | 190,189 | — | ↗ |
| 2022-01-05 | Hochman David P | Director | A-Award | A | Common Stock, par value $0.0001 per share | 127,083 | 0.00 | — | 291,669 | — | ↗ |
| 2021-11-19 | Taylor Andrew Lawrence | Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 2,000 | 0.51 | 1.0K | 135,682 | — | ↗ |
| 2021-11-19 | Pomeranz Mark | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 4,000 | 0.51 | 2.0K | 164,857 | — | ↗ |
| 2021-11-19 | Moran Timothy P. | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 10,000 | 0.52 | 5.2K | 482,701 | — | ↗ |
| 2021-11-11 | Ram Ravit | Officer | — | D | Stock Option (right to buy) | 2,250 | 14.80 | 33.3K | 0 | — | ↗ |
| 2021-11-11 | Amor Elad | Officer | — | D | Stock Option (right to buy) | 1,000 | 14.80 | 14.8K | 0 | — | ↗ |
| 2021-06-22 | Nelson Sonja | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-11 | Ram Ravit | Officer | — | D | Stock Option (right to buy) | 2,500 | 23.40 | 58.5K | 0 | — | ↗ |
| 2021-06-11 | Amor Elad | Officer | — | D | Stock Option (right to buy) | 1,000 | 23.40 | 23.4K | 0 | — | ↗ |
| 2021-05-01 | Ram Ravit | Officer | — | D | Stock Option (right to buy) | 2,500 | 87.20 | 218.0K | 0 | — | ↗ |
| 2021-02-17 | Taylor Andrew Lawrence | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 1.78 | 106.8K | 60,000 | — | ↗ |
| 2021-02-17 | Sherman Darren | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.78 | 53.4K | 30,000 | — | ↗ |
| 2021-02-17 | Pruden Gary J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 30,000 | 0.00 | — | 130,429 | — | ↗ |
| 2021-02-17 | Pomeranz Mark | Director / Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 1.78 | 115.7K | 65,000 | — | ↗ |
| 2021-02-17 | NUSSBAUM SAMUEL R MD | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.78 | 53.4K | 30,000 | — | ↗ |
| 2021-02-17 | Moran Timothy P. | Director / Officer | A-Award | A | Stock Option (right to buy) | 141,000 | 1.78 | 251.0K | 141,000 | — | ↗ |
| 2021-02-17 | Korangy Shervin J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 30,000 | 0.00 | — | 87,464 | — | ↗ |
| 2021-02-17 | Hochman David P | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.78 | 71.2K | 40,000 | — | ↗ |
| 2021-01-26 | FEINBERG LARRY N | — | S-Sale | D | Common Stock | 29,115 | 1.90 | 55.4K | 105,885 | — | ↗ |
| 2021-01-22 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 550,000 | 1.48 | 814.0K | 2,660,542 | — | ↗ |
| 2021-01-21 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 674,352 | 1.68 | 1.13M | 3,210,542 | — | ↗ |
| 2021-01-20 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 325,648 | 1.80 | 586.2K | 3,884,894 | — | ↗ |
| 2021-01-12 | Sherman Darren | Director | A-Award | A | Common Stock, par value $0.0001 per share | 9,144 | 0.00 | — | 51,890 | — | ↗ |
| 2021-01-12 | Pruden Gary J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 10,764 | 0.00 | — | 100,429 | — | ↗ |
| 2021-01-12 | NUSSBAUM SAMUEL R MD | Director | A-Award | A | Common Stock, par value $0.0001 per share | 8,334 | 0.00 | — | 47,464 | — | ↗ |
| 2021-01-12 | Korangy Shervin J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 8,334 | 0.00 | — | 57,464 | — | ↗ |
| 2021-01-12 | Hochman David P | Director | A-Award | A | Common Stock, par value $0.0001 per share | 15,741 | 0.00 | — | 92,114 | — | ↗ |
| 2020-12-17 | Sherman Darren | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 3,000 | 0.97 | 2.9K | 42,746 | — | ↗ |
| 2020-12-09 | Taylor Andrew Lawrence | Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 1,000 | 1.08 | 1.1K | 73,682 | — | ↗ |
| 2020-12-09 | Pomeranz Mark | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 1,000 | 1.08 | 1.1K | 95,857 | — | ↗ |
| 2020-12-04 | Moran Timothy P. | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 10,000 | 0.96 | 9.6K | 331,701 | — | ↗ |
| 2020-12-04 | Hochman David P | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 5,000 | 0.99 | 5.0K | 76,373 | — | ↗ |
| 2020-11-11 | Taylor Andrew Lawrence | Officer | A-Award | A | Stock Option (right to buy) | 78,000 | 0.74 | 57.7K | 78,000 | — | ↗ |
| 2020-11-11 | Pomeranz Mark | Director / Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 0.74 | 55.5K | 75,000 | — | ↗ |
| 2020-11-11 | Moran Timothy P. | Director / Officer | A-Award | A | Stock Option (right to buy) | 190,000 | 0.74 | 140.6K | 190,000 | — | ↗ |
| 2020-10-12 | Sherman Darren | Director | A-Award | A | Common Stock, par value $0.0001 per share | 10,346 | 0.00 | — | 39,746 | — | ↗ |
| 2020-10-12 | Pruden Gary J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 11,132 | 0.00 | — | 89,665 | — | ↗ |
| 2020-10-12 | NUSSBAUM SAMUEL R MD | Director | A-Award | A | Common Stock, par value $0.0001 per share | 9,430 | 0.00 | — | 39,130 | — | ↗ |
| 2020-10-12 | Korangy Shervin J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 9,430 | 0.00 | — | 49,130 | — | ↗ |
| 2020-10-12 | Hochman David P | Director | A-Award | A | Common Stock, par value $0.0001 per share | 18,466 | 0.00 | — | 71,373 | — | ↗ |
| 2020-07-10 | Sherman Darren | Director | A-Award | A | Common Stock, par value $0.0001 per share | 7,900 | 0.00 | — | 29,400 | — | ↗ |
| 2020-07-10 | Pruden Gary J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 7,700 | 0.00 | — | 78,533 | — | ↗ |
| 2020-07-10 | NUSSBAUM SAMUEL R MD | Director | A-Award | A | Common Stock, par value $0.0001 per share | 7,200 | 0.00 | — | 29,700 | — | ↗ |
| 2020-07-10 | Korangy Shervin J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 7,200 | 0.00 | — | 39,700 | — | ↗ |
| 2020-07-10 | Hochman David P | Director | A-Award | A | Common Stock, par value $0.0001 per share | 14,600 | 0.00 | — | 52,907 | — | ↗ |
| 2020-06-11 | Taylor Andrew Lawrence | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 1.17 | 105.3K | 90,000 | — | ↗ |
| 2020-06-11 | Pomeranz Mark | Director / Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 1.17 | 93.6K | 80,000 | — | ↗ |
| 2020-06-11 | Moran Timothy P. | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 1.17 | 234.0K | 200,000 | — | ↗ |
| 2020-02-06 | Taylor Andrew Lawrence | Officer | A-Award | A | Stock Option (right to buy) | 46,098 | 2.16 | 99.6K | 46,098 | — | ↗ |
| 2020-02-06 | Sherman Darren | Director | A-Award | A | Common Stock, par value $0.0001 per share | 12,500 | 0.00 | — | 21,500 | — | ↗ |
| 2020-02-06 | Pruden Gary J | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 2.16 | 27.0K | 12,500 | — | ↗ |
| 2020-02-06 | Pomeranz Mark | Director / Officer | A-Award | A | Stock Option (right to buy) | 40,336 | 2.16 | 87.1K | 40,336 | — | ↗ |
| 2020-02-06 | NUSSBAUM SAMUEL R MD | Director | A-Award | A | Common Stock, par value $0.0001 per share | 12,500 | 0.00 | — | 22,500 | — | ↗ |
| 2020-02-06 | Moran Timothy P. | Director / Officer | A-Award | A | Common Stock, par value $0.0001 per share | 103,720 | 0.00 | — | 321,701 | — | ↗ |
| 2020-02-06 | Korangy Shervin J | Director | A-Award | A | Common Stock, par value $0.0001 per share | 12,500 | 0.00 | — | 32,500 | — | ↗ |
| 2020-02-06 | Hochman David P | Director | A-Award | A | Common Stock, par value $0.0001 per share | 20,000 | 0.00 | — | 38,307 | — | ↗ |
| 2019-12-31 | Hochman David P | Director | J-Other | A | Warrants (right to buy) | 1,766 | 5.00 | 8.8K | 1,766 | — | ↗ |
| 2019-11-20 | Moran Timothy P. | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 10,000 | 1.54 | 15.4K | 217,981 | — | ↗ |
| 2019-11-18 | Jacobs Gary E. | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 17,000 | 1.54 | 26.2K | 771,289 | — | ↗ |
| 2019-07-01 | Pruden Gary J | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 8,333 | 3.00 | 25.0K | 58,333 | — | ↗ |
| 2019-07-01 | Pomeranz Mark | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 1,000 | 3.00 | 3.0K | 54,521 | — | ↗ |
| 2019-07-01 | Moran Timothy P. | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 3,333 | 3.00 | 10.0K | 207,981 | — | ↗ |
| 2019-07-01 | Jacobs Gary E. | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 8,333 | 3.00 | 25.0K | 754,289 | — | ↗ |
| 2019-07-01 | Hochman David P | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 10,000 | 3.00 | 30.0K | 110,000 | — | ↗ |
| 2019-07-01 | FEINBERG LARRY N | 10% Owner | P-Purchase | A | Common Stock | 35,000 | 3.02 | 105.6K | 135,000 | — | ↗ |
| 2019-06-27 | PERCEPTIVE ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 1,000,000 | 3.00 | 3.00M | 4,210,542 | — | ↗ |
| 2019-06-27 | FEINBERG LARRY N | 10% Owner | P-Purchase | A | Common Stock | 25,000 | 3.00 | 75.0K | 25,000 | — | ↗ |
| 2019-05-22 | Moran Timothy P. | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 5,000 | 3.38 | 16.9K | 204,648 | — | ↗ |
| 2019-02-13 | Taylor Andrew Lawrence | Officer | A-Award | A | Stock Option (right to buy) | 70,753 | 4.30 | 304.2K | 70,753 | — | ↗ |
| 2019-02-13 | Sherman Darren | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.30 | 107.5K | 25,000 | — | ↗ |
| 2019-02-13 | Pruden Gary J | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.30 | 107.5K | 25,000 | — | ↗ |
| 2019-02-13 | Pomeranz Mark | Director / Officer | A-Award | A | Common Stock, par value $0.0001 per share | 42,880 | 0.00 | — | 53,521 | — | ↗ |
| 2019-02-13 | NUSSBAUM SAMUEL R MD | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.30 | 107.5K | 25,000 | — | ↗ |
| 2019-02-13 | Moran Timothy P. | Director / Officer | A-Award | A | Common Stock, par value $0.0001 per share | 174,648 | 0.00 | — | 199,648 | — | ↗ |
| 2019-02-13 | Korangy Shervin J | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.30 | 107.5K | 25,000 | — | ↗ |
| 2019-02-13 | Jacobs Gary E. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 4.30 | 107.5K | 25,000 | — | ↗ |
| 2019-02-13 | Hochman David P | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 4.30 | 172.0K | 40,000 | — | ↗ |
| 2018-12-24 | Taylor Andrew Lawrence | Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 1,000 | 2.70 | 2.7K | 3,000 | — | ↗ |
| 2018-12-24 | Pomeranz Mark | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 2,500 | 2.70 | 6.8K | 10,641 | — | ↗ |
| 2018-12-24 | PERCEPTIVE ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 400,000 | 2.70 | 1.08M | 3,210,541 | — | ↗ |
| 2018-12-24 | Moran Timothy P. | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 10,000 | 2.70 | 27.0K | 25,000 | — | ↗ |
| 2018-12-24 | Jacobs Gary E. | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 10,000 | 2.70 | 27.0K | 745,956 | — | ↗ |
| 2018-12-24 | Hochman David P | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 20,000 | 2.70 | 54.0K | 100,000 | — | ↗ |
| 2018-12-19 | FEINBERG LARRY N | 10% Owner | — | I | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 2,077,000 | — | ↗ |
| 2018-11-27 | Jacobs Gary E. | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 7,100 | 3.48 | 24.7K | 735,956 | — | ↗ |
| 2018-11-19 | Moran Timothy P. | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 15,000 | 3.48 | 52.2K | 15,000 | — | ↗ |
| 2018-11-16 | Hochman David P | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 15,000 | 3.49 | 52.4K | 18,000 | — | ↗ |
| 2018-11-08 | Moran Timothy P. | Director / Officer | A-Award | A | Stock Option (right to buy) | 495,000 | 3.78 | 1.87M | 495,000 | — | ↗ |
| 2018-10-01 | Moran Timothy P. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-05-31 | Sherman Darren | Director | J-Other | A | Common Stock, par value $0.0001 per share | 2,000,000 | 0.00 | — | 2,000,000 | — | ↗ |
| 2018-05-31 | Orchestra BioMed, Inc. | 10% Owner | — | D | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 2,000,000 | — | ↗ |
| 2018-05-31 | Hochman David P | Director | J-Other | A | Common Stock, par value $0.0001 per share | 2,000,000 | 0.00 | — | 2,000,000 | — | ↗ |
| 2018-05-31 | Ascent Biomedical Ventures II, L.P. | — | J-Other | D | Common Stock, par value $0.0001 per share | 1,000,000 | 0.00 | — | 591,481 | — | ↗ |
| 2018-05-31 | ABV, LLC | — | J-Other | D | Common Stock, par value $0.0001 per share | 1,000,000 | 0.00 | — | 591,481 | — | ↗ |
| 2018-05-18 | Jacobs Gary E. | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 5,000 | 5.24 | 26.2K | 728,856 | — | ↗ |
| 2018-05-17 | Sherman Darren | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 per share | 1,000 | 5.55 | 5.6K | 9,000 | — | ↗ |
| 2018-05-17 | Hochman David P | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 per share | 5,000 | 5.49 | 27.5K | 80,000 | — | ↗ |
| 2018-03-27 | Pruden Gary J | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 4.58 | 229.0K | 50,000 | — | ↗ |
| 2018-02-16 | Taylor Andrew Lawrence | Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 2,000 | 5.00 | 10.0K | 2,000 | — | ↗ |
| 2018-02-16 | Sherman Darren | Director / 10% Owner | J-Other | A | Warrants (right to buy) | 300 | 5.00 | 1.5K | 300 | — | ↗ |
| 2018-02-16 | Pruden Gary J | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 50,000 | 5.00 | 250.0K | 50,000 | — | ↗ |
| 2018-02-16 | Pomeranz Mark | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 8,000 | 5.00 | 40.0K | 8,141 | — | ↗ |
| 2018-02-16 | PERCEPTIVE ADVISORS LLC | 10% Owner | J-Other | A | Warrant (right to buy) | 180,055 | 5.00 | 900.3K | 180,055 | — | ↗ |
| 2018-02-16 | NUSSBAUM SAMUEL R MD | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 10,000 | 5.00 | 50.0K | 10,000 | — | ↗ |
| 2018-02-16 | Korangy Shervin J | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 20,000 | 5.00 | 100.0K | 20,000 | — | ↗ |
| 2018-02-16 | Jacobs Gary E. | Director | C-Conversion | A | Common Stock, par value $0.0001 per share | 63,289 | 0.00 | — | 723,856 | — | ↗ |
| 2018-02-16 | Hochman David P | Director / 10% Owner | C-Conversion | A | Common Stock, par value $0.0001 per share | 65,038 | 0.00 | — | 1,159,968 | — | ↗ |
| 2018-02-16 | Ascent Biomedical Ventures II, L.P. | 10% Owner | C-Conversion | D | Series A Convertible Preferred Stock | 144,352 | 0.00 | — | 0 | — | ↗ |
| 2018-02-16 | ABV, LLC | 10% Owner | C-Conversion | D | Series A Convertible Preferred Stock | 26,241 | 0.00 | — | 0 | — | ↗ |
| 2018-02-14 | PERCEPTIVE ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 10,000 | 5.00 | 50.0K | 2,810,541 | — | ↗ |
| 2018-02-13 | Taylor Andrew Lawrence | Officer | — | D | Stock Option (right to buy) | 240,000 | 4.50 | 1.08M | 0 | — | ↗ |
| 2018-02-13 | Sherman Darren | Director / 10% Owner | — | I | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 1,094,930 | — | ↗ |
| 2018-02-13 | Pruden Gary J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-02-13 | Pomeranz Mark | Director / Officer | — | D | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 141 | — | ↗ |
| 2018-02-13 | PERCEPTIVE ADVISORS LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,544,155 | — | ↗ |
| 2018-02-13 | Orchestra Medical Ventures II GP, LLC | 10% Owner | — | I | Series A Convertible Preferred Stock | 99,748 | 0.00 | — | 0 | — | ↗ |
| 2018-02-13 | Orchestra MOTUS Co-Investment Partners, LLC | 10% Owner | — | D | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 1,094,930 | — | ↗ |
| 2018-02-13 | NUSSBAUM SAMUEL R MD | Director | — | D | Stock Option (right to buy) | 50,000 | 4.50 | 225.0K | 0 | — | ↗ |
| 2018-02-13 | Korangy Shervin J | Director | — | D | Stock Option (right to buy) | 65,000 | 4.50 | 292.5K | 0 | — | ↗ |
| 2018-02-13 | Jacobs Gary E. | Director | — | D | Stock Option (right to buy) | 92,500 | 4.50 | 416.3K | 0 | — | ↗ |
| 2018-02-13 | Hochman David P | Director / Officer / 10% Owner | — | I | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 83,352 | — | ↗ |
| 2018-02-13 | Ascent Biomedical Ventures II, L.P. | 10% Owner | — | D | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 1,447,129 | — | ↗ |
| 2018-02-13 | ABV, LLC | 10% Owner | — | I | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 1,447,129 | — | ↗ |
| 2016-12-22 | Sherman Darren | Director / 10% Owner | — | I | Warrant (right to buy) | 69,136 | 5.00 | 345.7K | 0 | — | ↗ |
| 2016-12-22 | PERCEPTIVE ADVISORS LLC | 10% Owner | — | I | Warrant (right to buy) | 66,000 | 5.00 | 330.0K | 0 | — | ↗ |
| 2016-12-22 | Orchestra Medical Ventures II GP, LLC | 10% Owner | — | I | Warrant (right to buy) | 108,838 | 5.00 | 544.2K | 0 | — | ↗ |
| 2016-12-22 | Orchestra MOTUS Co-Investment Partners, LLC | 10% Owner | — | D | Warrant (right to buy) | 69,136 | 5.00 | 345.7K | 0 | — | ↗ |
| 2016-12-22 | Jacobs Gary E. | Director | — | I | Warrant (right to buy) | 68,906 | 5.00 | 344.5K | 0 | — | ↗ |
| 2016-12-22 | Hochman David P | Director / Officer / 10% Owner | — | I | Warrant (right to buy) | 108,838 | 5.00 | 544.2K | 0 | — | ↗ |
| 2016-12-22 | Ascent Biomedical Ventures II, L.P. | 10% Owner | — | D | Warrant (right to buy) | 156,734 | 5.00 | 783.7K | 0 | — | ↗ |
| 2016-12-22 | ABV, LLC | 10% Owner | — | I | Warrant (right to buy) | 27,433 | 5.00 | 137.2K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-8.1K
Shares Outstanding
6.39M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Timothy P. Moran Former Chief Executive Officer | 475.0K | — | 79.4K | 79.4K | — | 49.8K | 683.6K | 23.23% | ↗ |
| 2 | 2022 | Mark Pomeranz President and Chief Executive Officer; Former Chief Operating Officer | 385.0K | — | 43.1K | 43.1K | — | 44.3K | 515.5K | 16.72% | ↗ |
| 3 | 2022 | Andrew Taylor Former Chief Financial Officer | 330.0K | — | 43.1K | 43.1K | — | 49.8K | 466.0K | 18.50% | ↗ |
| 4 | 2021 | Timothy P. Moran Chief Executive Officer | 475.0K | 256.1K | 251.0K | 202.8K | — | 47.3K | 1.24M | 36.56% | ↗ |
| 5 | 2021 | Timothy P. Moran Former Chief Executive Officer | 475.0K | 265.1K | 251.0K | 202.8K | — | 47.3K | 1.24M | 36.56% | ↗ |
| 6 | 2021 | Mark Pomeranz President and Chief Operating Officer | 385.0K | 229.0K | 115.7K | 93.7K | — | 34.8K | 858.0K | 24.41% | ↗ |
| 7 | 2021 | Mark Pomeranz President and Chief Executive Officer; Former Chief Operating Officer | 385.0K | 229.0K | 115.7K | 93.5K | — | 34.8K | 858.0K | 24.38% | ↗ |
| 8 | 2021 | Andrew Taylor Former Chief Financial Officer | 310.0K | 115.3K | 106.8K | 86.3K | — | 42.3K | 660.7K | 29.22% | ↗ |
| 9 | 2021 | Andrew Taylor Chief Financial Officer | 310.0K | 115.3K | 106.8K | 86.3K | — | 42.3K | 660.7K | 29.22% | ↗ |
| 10 | 2020 | Timothy P. Moran Chief Executive Officer | 475.0K | 262.2K | 224.0K | 408.7K | — | 558.9K | 1.93M | 32.80% | ↗ |
| 11 | 2020 | Mark Pomeranz President and Chief Operating Officer | 385.0K | 174.2K | 87.1K | 160.8K | — | 18.0K | 825.1K | 30.04% | ↗ |
| 12 | 2020 | Andrew Taylor Chief Financial Officer | 310.0K | 112.2K | 99.6K | 178.7K | — | 25.6K | 726.1K | 38.32% | ↗ |
| 13 | 2019 | Timothy P. Moran Chief Executive Officer | 475.0K | 213.8K | 41.7K | 79.2K | — | 849.8K | 1.66M | 7.28% | ↗ |
| 14 | 2019 | Mark Pomeranz President and Chief Operating Officer | 385.0K | 153.0K | 185.2K | 351.6K | — | 16.2K | 1.09M | 49.20% | ↗ |
| 15 | 2019 | Andrew Taylor Chief Financial Officer | 307.5K | 92.8K | 101.9K | 194.0K | — | 23.1K | 719.2K | 41.14% | ↗ |
| 16 | 2018 | Timothy P. Moran Chief Executive Officer | 118.8K | 57.0K | 810.2K | 1.18M | — | 247.9K | 2.41M | 82.41% | ↗ |
| 17 | 2018 | Mark Pomeranz President and Chief Operating Officer | 359.5K | 110.7K | — | — | — | 31.8K | 502.0K | 0.00% | ↗ |
| 18 | 2018 | Andrew Taylor Chief Financial Officer | 295.0K | 29.8K | — | — | — | 31.8K | 356.5K | 0.00% | ↗ |
| 19 | 2017 | Mark Pomeranz President and Chief Operating Officer | 350.0K | 87.5K | 639.00 | 1.12M | — | 30.7K | 1.59M | 70.58% | ↗ |
| 20 | 2017 | Andrew Taylor Chief Financial Officer | 110.6K | 27.0K | — | 601.1K | — | 9.5K | 748.2K | 80.34% | ↗ |
| 21 | 2017 | Timothy P. Moran Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ravit Ram | Chief Financial Officer & Vice President of Global Operations | 371.6K | female |
| Elad Amor | Chief Accounting Officer | 349.9K | male |
| Jeff Varsalone | President & Director | — | — |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MOTS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
